CN102271683B - 恶性血液病的治疗 - Google Patents

恶性血液病的治疗 Download PDF

Info

Publication number
CN102271683B
CN102271683B CN200980154097.9A CN200980154097A CN102271683B CN 102271683 B CN102271683 B CN 102271683B CN 200980154097 A CN200980154097 A CN 200980154097A CN 102271683 B CN102271683 B CN 102271683B
Authority
CN
China
Prior art keywords
compound
cells
treatment
cell
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980154097.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102271683A (zh
Inventor
M·W·加勒廷
R·G·尤里奇
N·吉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Calistoga LLC
Original Assignee
Gidded Calistoga Co
Gilead Calistoga LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gidded Calistoga Co, Gilead Calistoga LLC filed Critical Gidded Calistoga Co
Priority to CN201410246030.0A priority Critical patent/CN104042618B/zh
Publication of CN102271683A publication Critical patent/CN102271683A/zh
Application granted granted Critical
Publication of CN102271683B publication Critical patent/CN102271683B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200980154097.9A 2008-11-13 2009-11-13 恶性血液病的治疗 Expired - Fee Related CN102271683B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410246030.0A CN104042618B (zh) 2008-11-13 2009-11-13 恶性血液病的治疗

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US11443408P 2008-11-13 2008-11-13
US61/114,434 2008-11-13
US14284509P 2009-01-06 2009-01-06
US61/142,845 2009-01-06
US15505709P 2009-02-24 2009-02-24
US61/155,057 2009-02-24
US18076809P 2009-05-22 2009-05-22
US61/180,768 2009-05-22
US23127809P 2009-08-04 2009-08-04
US61/231,278 2009-08-04
US24519609P 2009-09-23 2009-09-23
US61/245,196 2009-09-23
PCT/US2009/064471 WO2010057048A1 (en) 2008-11-13 2009-11-13 Therapies for hematologic malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410246030.0A Division CN104042618B (zh) 2008-11-13 2009-11-13 恶性血液病的治疗

Publications (2)

Publication Number Publication Date
CN102271683A CN102271683A (zh) 2011-12-07
CN102271683B true CN102271683B (zh) 2014-07-09

Family

ID=41604034

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980154097.9A Expired - Fee Related CN102271683B (zh) 2008-11-13 2009-11-13 恶性血液病的治疗
CN201410246030.0A Expired - Fee Related CN104042618B (zh) 2008-11-13 2009-11-13 恶性血液病的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410246030.0A Expired - Fee Related CN104042618B (zh) 2008-11-13 2009-11-13 恶性血液病的治疗

Country Status (13)

Country Link
US (5) US20100202963A1 (enExample)
EP (2) EP2355828B1 (enExample)
JP (3) JP5794919B2 (enExample)
KR (3) KR20170060179A (enExample)
CN (2) CN102271683B (enExample)
AU (6) AU2009313878B2 (enExample)
CA (3) CA2975473C (enExample)
ES (1) ES2674719T3 (enExample)
IL (1) IL212851A0 (enExample)
NZ (3) NZ611764A (enExample)
PT (1) PT2355828T (enExample)
SG (2) SG10201703911XA (enExample)
WO (1) WO2010057048A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
ES2607804T3 (es) 2004-05-13 2017-04-04 Icos Corporation Quinazolinones como inhibidores de la fosfatidilinositol humana 3-quinasa delta
EP1750714A1 (en) * 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
KR101653842B1 (ko) 2008-01-04 2016-09-02 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (zh) * 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP2421536B1 (en) * 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
NZ717373A (en) 2010-06-03 2017-11-24 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
JP2013528228A (ja) * 2010-06-11 2013-07-08 ギリアード カリストガ エルエルシー キナゾリノン化合物による選択した患者における血液系障害を処置する方法
WO2011163195A1 (en) * 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
DE102010039631A1 (de) * 2010-08-22 2012-02-23 Ulrich Schubert Pharmazeutische Zusammensetzungen mit immunmodulatorischen Eigenschaften
WO2012064671A1 (en) * 2010-11-08 2012-05-18 The Ohio State University Research Foundation Compositions and methods for increasing drug efficacy in cancer
JP2014500259A (ja) * 2010-11-17 2014-01-09 ニーキ ファーマ インコーポレイテッド 血液癌を処置する方法
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
WO2012121953A1 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
AU2012229266A1 (en) * 2011-03-11 2013-05-02 Gilead Calistoga Llc Combination therapies for hematologic malignancies
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AU2012236834B2 (en) 2011-03-28 2015-12-10 Mei Pharma, Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
WO2013082540A1 (en) * 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
PL2790705T3 (pl) 2011-12-15 2018-06-29 Novartis Ag Zastosowanie inhibitorów czynności lub funkcji PI3K
WO2013134288A1 (en) * 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
AU2015252058A1 (en) * 2012-03-05 2015-11-19 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR102216606B1 (ko) 2012-07-04 2021-02-17 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
WO2014071109A1 (en) * 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
IL241407B (en) * 2013-03-13 2022-06-01 Univ California Compositions comprising anti-cd38 antibodies and carfilzomib
HK1221174A1 (zh) * 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
US20140377258A1 (en) * 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
AU2014298486B2 (en) * 2013-07-30 2019-01-24 Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch for the treatment of hematological neoplasms
JP6584391B2 (ja) * 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
CN105849108A (zh) 2013-12-20 2016-08-10 吉利德卡利斯托加公司 磷脂酰肌醇3-激酶抑制剂的制备方法
WO2015160986A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
KR20170007480A (ko) 2014-05-27 2017-01-18 리젠 파마슈티컬스 소시에떼 아노님 약제학적 제형에 사용하기 위한 pi3k 델타 선택적 억제제의 개선된 형태
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
CN105503877A (zh) 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途
PH12017501538B1 (en) 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US11298338B2 (en) 2016-06-06 2022-04-12 University Of Iowa Research Foundation Compositions and methods for cancer therapy
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
KR101932146B1 (ko) * 2016-07-14 2018-12-24 주식회사 바이오웨이 Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물
EP3487525A4 (en) * 2016-07-22 2020-03-18 Seattle Genetics, Inc. COMBINATION THERAPY WITH CD19-ADC AND RCHP
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN117860758A (zh) 2017-05-23 2024-04-12 梅制药公司 联合疗法
WO2018222831A1 (en) * 2017-05-31 2018-12-06 The Children's Medical Center Corporation TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
SG11202000523PA (en) * 2017-07-31 2020-02-27 The Trustees Of Columbia Univeristy In The City Of New York Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.
CN112469418A (zh) 2018-06-01 2021-03-09 因赛特公司 治疗pi3k相关病症的给药方案
CN111658636B (zh) * 2020-06-12 2021-04-13 桂林医学院 穿心莲内酯与地塞米松联用在制备复方抗急性淋巴细胞白血病药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113556A1 (en) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2005120511A1 (en) * 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1249281B (enExample) 1963-05-18
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US3897432A (en) 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
NL7204972A (enExample) 1971-04-21 1972-10-24
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2644265C2 (de) 1976-09-30 1983-02-10 Bayer Ag, 5090 Leverkusen Chinazoline
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2812635A1 (de) 1978-03-22 1979-09-27 Bayer Ag Heterocyclische verbindungen
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
CH671155A5 (enExample) 1986-08-18 1989-08-15 Clinical Technologies Ass
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US6696250B1 (en) 1986-12-03 2004-02-24 Competitive Technologies, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
DK0525960T3 (da) 1991-06-18 1996-04-15 American Home Prod Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
EP1157698A3 (en) 1994-08-12 2002-05-02 Pro-Neuron, Inc. Treatment of inflammatory diseases with oxypurine nucleosides
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5948664A (en) 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ES2198546T3 (es) 1996-05-15 2004-02-01 Pfizer Inc. 4(3h)-quinazolinonas 2,3,6 trisustituidas.
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
PT958296E (pt) 1996-12-31 2003-11-28 Reddys Lab Ltd Dr Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
ATE267817T1 (de) 1997-02-28 2004-06-15 Pfizer Prod Inc Atropisomere von 3-aryl-4(3h)-chinazolinonen und ihre verwendung als ampa-rezeptor
EP0884310B1 (en) 1997-06-09 2005-09-07 Pfizer Products Inc. Quinazolin-4-one ampa antagonists
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
CA2317093A1 (en) 1998-01-08 1999-07-15 Joel M. Linden A2a adenosine receptor agonists
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
WO2000027428A1 (en) * 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
US6046049A (en) 1999-07-19 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p110 delta expression
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
CN1891693A (zh) 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
AU2001229727B2 (en) 2000-02-07 2004-10-14 Bristol-Myers Squibb Co. 3-aminopyrazole inhibitors of cyclin dependent kinases
WO2001081346A2 (en) 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2003106622A2 (en) 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
CA2493843C (en) 2002-07-10 2012-04-17 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
GB0217777D0 (en) 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CA2400254A1 (en) 2002-09-19 2004-03-19 University Health Network Compositions and methods for treating heart disease
ATE411996T1 (de) 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
JP2006510661A (ja) 2002-12-06 2006-03-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体
WO2004056820A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
EP1611119A1 (en) 2003-04-03 2006-01-04 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
JP2006526605A (ja) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 治療剤としての３−置換インドール類及びそれらの誘導体
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
WO2004108709A1 (en) 2003-06-05 2004-12-16 Warner-Lambert Company Llc Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents
MXPA05013210A (es) 2003-06-05 2006-03-09 Warner Lambert Co Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
BRPI0411092A (pt) 2003-06-05 2006-07-18 Warner Lambert Co benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
EP1636210A1 (en) 2003-06-05 2006-03-22 Warner-Lambert Company LLC Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2005067901A2 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
US20100009929A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
CN100441222C (zh) 2005-12-09 2008-12-10 中国科学院广州生物医药与健康研究院 化合物ps-341在制备治疗急性髓性白血病药物中的应用
AR057227A1 (es) * 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
JP2010516767A (ja) * 2007-01-23 2010-05-20 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンおよびｉ．ａ．ボルテゾミブを含む併用療法
WO2009052467A1 (en) 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Methods of identifying pi-3-kinase inhibitor resistance
US20090131512A1 (en) 2007-10-31 2009-05-21 Dynavax Technologies Corp. Inhibition of type I in IFN production
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (zh) * 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
CA2745280A1 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
ES2634492T3 (es) 2008-12-24 2017-09-28 Prana Biotechnology Ltd Compuestos de quinazolinona
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP2421536B1 (en) 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
JP2013504604A (ja) 2009-09-18 2013-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤としてのキナゾリノン誘導体
AU2012229266A1 (en) 2011-03-11 2013-05-02 Gilead Calistoga Llc Combination therapies for hematologic malignancies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113556A1 (en) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2005120511A1 (en) * 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation

Also Published As

Publication number Publication date
US9238070B2 (en) 2016-01-19
KR20170060179A (ko) 2017-05-31
CA3092449A1 (en) 2010-05-20
JP2015155436A (ja) 2015-08-27
CN102271683A (zh) 2011-12-07
EP2355828B1 (en) 2018-05-30
ES2674719T3 (es) 2018-07-03
AU2019213337C1 (en) 2021-11-25
AU2018204264B2 (en) 2019-05-16
JP2017008088A (ja) 2017-01-12
CA2743642C (en) 2017-09-19
KR20110105771A (ko) 2011-09-27
CA2743642A1 (en) 2010-05-20
AU2019213337B2 (en) 2021-03-11
EP3427739A1 (en) 2019-01-16
US20190083498A1 (en) 2019-03-21
AU2016201634B2 (en) 2016-12-01
AU2018247326A1 (en) 2018-11-08
US20100202963A1 (en) 2010-08-12
SG195655A1 (en) 2013-12-30
AU2017200837A1 (en) 2017-03-02
CN104042618B (zh) 2018-02-16
AU2018204264C1 (en) 2020-01-23
AU2009313878A1 (en) 2010-05-20
AU2019213337A1 (en) 2019-08-29
PT2355828T (pt) 2018-07-02
NZ631024A (en) 2016-04-29
CA2975473A1 (en) 2010-05-20
US20200368243A1 (en) 2020-11-26
AU2018204264A1 (en) 2018-07-05
AU2016201634A1 (en) 2016-04-07
JP2012508775A (ja) 2012-04-12
EP2355828A1 (en) 2011-08-17
CA2975473C (en) 2021-01-19
CN104042618A (zh) 2014-09-17
AU2017200837B2 (en) 2018-07-12
IL212851A0 (en) 2011-07-31
US20140323439A1 (en) 2014-10-30
WO2010057048A1 (en) 2010-05-20
JP5794919B2 (ja) 2015-10-14
SG10201703911XA (en) 2017-06-29
KR20160091440A (ko) 2016-08-02
NZ592880A (en) 2013-06-28
AU2009313878B2 (en) 2016-01-07
KR101664511B1 (ko) 2016-10-11
US20140066386A1 (en) 2014-03-06
NZ611764A (en) 2015-01-30
AU2018247326B2 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
CN102271683B (zh) 恶性血液病的治疗
JP2012508775A5 (enExample)
EP3187184A1 (en) Combination therapies for hematologic malignancies
US10154998B2 (en) Therapies for hematologic malignancies
HK40000474A (en) Therapies for hematologic malignancies
OA16585A (en) Combination therapies for hematologic malignancies.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American California

Applicant after: Gilead Calistoga LLC

Address before: American California

Applicant before: Calistoga Pharmaceuticals Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CALISTOGA PHARMACEUTICALS INC. TO: GILEAD CALISTOGA LLC

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: American California

Patentee after: GILEAD CALISTOGA LLC

Address before: American California

Patentee before: Gilead Calistoga LLC

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140709

Termination date: 20171113